Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (24)

« Back to Publications

Phase II multicentre double-blind randomised controlled trial of a Bivalent VaccInation against Salmonella Typhi and Paratyphi A (BiVISTA) using a controlled human infection model of paratyphoid A infection: study protocol.

Paganotti Vicentine M. et al, (2026), BMJ Open, 16

Natural and vaccine mediated correlates of protection against enteric fever

Jones E., (2024)

The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.

Kulkarni PS. et al, (2024), Lancet, 403, 1554 - 1562

Immune responses to typhoid conjugate vaccine in a two dose schedule among Nepalese children <2 years of age.

Bijukchhe SM. et al, (2024), Vaccine, 42, 2018 - 2025

Molecular correlates of vaccine-induced protection against typhoid fever.

Zhu H. et al, (2023), J Clin Invest, 133

Genetic Susceptibility to Enteric Fever in Experimentally Challenged Human Volunteers.

Barton A. et al, (2022), Infect Immun, 90

Distinct glycosylation and functional profile of typhoid vaccine-induced antibodies in a UK challenge study and Nepalese children

Stockdale LK. et al, (2022), Frontiers in Analytical Science, 2

Efficacy of typhoid conjugate vaccine in Nepal: final results of a phase 3, randomised, controlled trial.

Shakya M. et al, (2021), Lancet Glob Health, 9, e1561 - e1568

A Salmonella Typhi Controlled Human Infection Study for Assessing Correlation between Bactericidal Antibodies and Protection against Infection Induced by Typhoid Vaccination.

Jones E. et al, (2021), Microorganisms, 9

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Voysey M. et al, (2021), Lancet, 397, 881 - 891

Vi-specific serological correlates of protection for typhoid fever.

Jin C. et al, (2021), J Exp Med, 218

Association of Antibody-Dependent Neutrophil Phagocytosis With Distinct Antibody Glycosylation Profiles Following Typhoid Vaccination

Johnson M. et al, (2021), Frontiers in Tropical Diseases, 2

Persistence of Antibody After a Vi-Tetanus Toxoid Conjugate Vaccine and Effect of Boosting With a Plain Polysaccharide Vaccine on Vi Antibody and Antigen-Specific B Cells

Bentley T. et al, (2021), Frontiers in Tropical Diseases, 2

Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison.

National SARS-CoV-2 Serology Assay Evaluation Group ., (2020), Lancet Infect Dis, 20, 1390 - 1400

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 - Authors' reply.

Voysey M. and Pollard AJ., (2020), Lancet, 396, 1486 - 1487

Load More